Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictive factors for 6 vs 12 cycles of Folfiri-Bevacizumab in metastatic colorectal cancer.
Formica V, Ionta MT, Massidda B, Vessia G, Maiorino L, Casaretti R, Natale D, Barberis G, Filippelli G, Greco E, Blasi L, Mancarella S, Russo A, Barbato E, Lullo LD, Roselli M. Formica V, et al. Among authors: casaretti r. Oncotarget. 2017 Dec 17;9(2):2876-2886. doi: 10.18632/oncotarget.23355. eCollection 2018 Jan 5. Oncotarget. 2017. PMID: 29416820 Free PMC article.
Concurrent modulation of 5-fluorouracil with methotrexate and L-leucovorin: an effective and moderately toxic regimen for the treatment of advanced colorectal carcinoma. A multicenter phase II study of the Southern Italy Cooperative Oncology Group.
Comella P, Lorusso V, Casaretti R, De Lucia L, Cartení G, Manzione L, Mancarella S, De Lena M, Comella G. Comella P, et al. Among authors: casaretti r. Tumori. 1999 Nov-Dec;85(6):465-72. doi: 10.1177/030089169908500608. Tumori. 1999. PMID: 10774567 Clinical Trial.
A tailored regimen including capecitabine and oxaliplatin for treating elderly patients with metastatic colorectal carcinoma Southern Italy Cooperative Oncology Group trial 0108.
Comella P, Gambardella A, Farris A, Maiorino L, Natale D, Massidda B, Casaretti R, Tafuto S, Lorusso V, Leo S; Southern Italy Cooperative Oncology Group. Comella P, et al. Among authors: casaretti r. Crit Rev Oncol Hematol. 2005 Feb;53(2):133-9. doi: 10.1016/j.critrevonc.2004.10.008. Crit Rev Oncol Hematol. 2005. PMID: 15661564 Clinical Trial.
Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy Cooperative Oncology Group phase II study.
Comella P, Massidda B, Palmeri S, Farris A, Lucia LD, Natale D, Maiorino L, Tafuto S, Cataldis GD, Casaretti R. Comella P, et al. Among authors: casaretti r. Cancer Chemother Pharmacol. 2005 Nov;56(5):481-6. doi: 10.1007/s00280-005-1003-6. Epub 2005 May 18. Cancer Chemother Pharmacol. 2005. PMID: 15902461 Clinical Trial.
Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
Comella P, Natale D, Farris A, Gambardella A, Maiorino L, Massidda B, Casaretti R, Tafuto S, Lorusso V, Leo S, Cannone M. Comella P, et al. Among authors: casaretti r. Cancer. 2005 Jul 15;104(2):282-9. doi: 10.1002/cncr.21167. Cancer. 2005. PMID: 15948167 Free article. Clinical Trial.
Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401.
Comella P, Massidda B, Filippelli G, Farris A, Natale D, Barberis G, Maiorino L, Palmeri S, Cannone M, Condemi G; Southern Italy Cooperative Oncology Group. Comella P, et al. J Cancer Res Clin Oncol. 2009 Feb;135(2):217-26. doi: 10.1007/s00432-008-0454-7. Epub 2008 Aug 22. J Cancer Res Clin Oncol. 2009. PMID: 18719941 Clinical Trial.
Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group.
Comella P, Lorusso V, Maiorino L, Casaretti R, Cannone M, Massidda B, Putzu C, Leo S, Roselli M, Mancarella S, Palmeri S, Greco E, Vessia G, Sandomenico C, Franco L. Comella P, et al. Among authors: casaretti r. Cancer Chemother Pharmacol. 2009 Oct;64(5):893-9. doi: 10.1007/s00280-009-0938-4. Epub 2009 Feb 3. Cancer Chemother Pharmacol. 2009. PMID: 19189106 Free article. Clinical Trial.
First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis.
Ottaiano A, De Stefano A, Capozzi M, Nappi A, De Divitiis C, Romano C, Silvestro L, Cassata A, Casaretti R, Tafuto S, Caraglia M, Berretta M, Nasti G, Avallone A. Ottaiano A, et al. Among authors: casaretti r. Front Pharmacol. 2018 May 3;9:441. doi: 10.3389/fphar.2018.00441. eCollection 2018. Front Pharmacol. 2018. PMID: 29773991 Free PMC article. Review.
Integration of stereotactic radiotherapy in the treatment of metastatic colorectal cancer patients: a real practice study with long-term outcome and prognostic factors.
Ottaiano A, Scotti V, De Divitiis C, Capozzi M, Romano C, Cassata A, Casaretti R, Silvestro L, Nappi A, Vicario V, De Stefano A, Tafuto S, Berretta M, Nasti G, Avallone A. Ottaiano A, et al. Among authors: casaretti r. Oncotarget. 2018 Oct 16;9(81):35251-35265. doi: 10.18632/oncotarget.25834. eCollection 2018 Oct 16. Oncotarget. 2018. PMID: 30443292 Free PMC article.
54 results